Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 113

1.

Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial.

Sternberg CN, Skoneczna I, Kerst JM, Albers P, Fossa SD, Agerbaek M, Dumez H, de Santis M, Théodore C, Leahy MG, Chester JD, Verbaeys A, Daugaard G, Wood L, Witjes JA, de Wit R, Geoffrois L, Sengelov L, Thalmann G, Charpentier D, Rolland F, Mignot L, Sundar S, Symonds P, Graham J, Joly F, Marreaud S, Collette L, Sylvester R; for the European Organisation for Research and Treatment of Cancer Genito-Urinary Cancers Group; Groupe d'Etude des Tumeurs Urogénitales; National Cancer Research Institute Bladder Cancer Study Group; National Cancer Institute of Canada Clinical Trials Group; German Association of Urologic Oncology (AUO).

Lancet Oncol. 2014 Dec 10. pii: S1470-2045(14)71160-X. doi: 10.1016/S1470-2045(14)71160-X. [Epub ahead of print]

PMID:
25498218
[PubMed - as supplied by publisher]
2.

Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.

Fizazi K, Pagliaro L, Laplanche A, Fléchon A, Mardiak J, Geoffrois L, Kerbrat P, Chevreau C, Delva R, Rolland F, Theodore C, Roubaud G, Gravis G, Eymard JC, Malhaire JP, Linassier C, Habibian M, Martin AL, Journeau F, Reckova M, Logothetis C, Culine S.

Lancet Oncol. 2014 Dec;15(13):1442-50. doi: 10.1016/S1470-2045(14)70490-5. Epub 2014 Nov 13.

PMID:
25456363
[PubMed - in process]
3.

Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model.

Gravis G, Boher JM, Fizazi K, Joly F, Priou F, Marino P, Latorzeff I, Delva R, Krakowski I, Laguerre B, Walz J, Rolland F, Théodore C, Deplanque G, Ferrero JM, Pouessel D, Mourey L, Beuzeboc P, Zanetta S, Habibian M, Berdah JF, Dauba J, Baciuchka M, Platini C, Linassier C, Labourey JL, Machiels JP, Kouri CE, Ravaud A, Suc E, Eymard JC, Hasbini A, Bousquet G, Soulie M, Oudard S.

Eur Urol. 2014 Sep 29. pii: S0302-2838(14)00959-2. doi: 10.1016/j.eururo.2014.09.022. [Epub ahead of print]

PMID:
25277272
[PubMed - as supplied by publisher]
4.

Docetaxel rechallenge in patients with metastatic castration-resistant prostate cancer.

Oudard S, Kramer G, Caffo O, Creppy L, Loriot Y, Hansen S, Holmberg M, Rolland F, Machiels JP, Krainer M.

BJU Int. 2014 Jun 20. doi: 10.1111/bju.12845. [Epub ahead of print]

PMID:
24947139
[PubMed - as supplied by publisher]
5.

An unusual tracheal tumour.

Rolland F, Laberge F, Delage A.

Can Respir J. 2014 November/December;21(6):331-332. Epub 2014 Jun 10. No abstract available.

PMID:
24914706
[PubMed - as supplied by publisher]
6.

Combining gemcitabine, cisplatin, and ifosfamide (GIP) is active in patients with relapsed metastatic germ-cell tumors (GCT): a prospective multicenter GETUG phase II trial.

Fizazi K, Gravis G, Flechon A, Geoffrois L, Chevreau C, Laguerre B, Delva R, Eymard JC, Rolland F, Houede N, Laplanche A, Burcoveanu D, Culine S.

Ann Oncol. 2014 May;25(5):987-91. doi: 10.1093/annonc/mdu099. Epub 2014 Mar 4.

PMID:
24595454
[PubMed - indexed for MEDLINE]
7.

An international phase 3 trial in head and neck cancer: quality of life and symptom results: EORTC 24954 on behalf of the EORTC Head and Neck and the EORTC Radiation Oncology Group.

Bottomley A, Tridello G, Coens C, Rolland F, Tesselaar ME, Leemans CR, Hupperets P, Licitra L, Vermorken JB, Van Den Weyngaert D, Truc G, Barillot I, Lefebvre JL.

Cancer. 2014 Feb 1;120(3):390-8. doi: 10.1002/cncr.28392. Epub 2013 Oct 25.

PMID:
24452673
[PubMed - indexed for MEDLINE]
8.

Patients' self-assessment versus investigators' evaluation in a phase III trial in non-castrate metastatic prostate cancer (GETUG-AFU 15).

Gravis G, Marino P, Joly F, Oudard S, Priou F, Esterni B, Latorzeff I, Delva R, Krakowski I, Laguerre B, Rolland F, Théodore C, Deplanque G, Ferrero JM, Pouessel D, Mourey L, Beuzeboc P, Zanetta S, Habibian M, Berdah JF, Dauba J, Baciuchka M, Platini C, Linassier C, Labourey JL, Machiels JP, El Kouri C, Ravaud A, Suc E, Eymard JC, Hasbini A, Bousquet G, Soulie M, Fizazi K.

Eur J Cancer. 2014 Mar;50(5):953-62. doi: 10.1016/j.ejca.2013.11.034. Epub 2014 Jan 11.

PMID:
24424105
[PubMed - indexed for MEDLINE]
9.

A phase II trial of sunitinib in patients with renal cell cancer and untreated brain metastases.

Chevreau C, Ravaud A, Escudier B, Amela E, Delva R, Rolland F, Tosi D, Oudard S, Blanc E, Ferlay C, Négrier S; French Group on Renal Cancer.

Clin Genitourin Cancer. 2014 Feb;12(1):50-4. doi: 10.1016/j.clgc.2013.09.008. Epub 2013 Sep 28.

PMID:
24268852
[PubMed - indexed for MEDLINE]
10.

Sucrose induction of anthocyanin biosynthesis is mediated by DELLA.

Li Y, Van den Ende W, Rolland F.

Mol Plant. 2014 Mar;7(3):570-2. doi: 10.1093/mp/sst161. Epub 2013 Nov 16. No abstract available.

PMID:
24243681
[PubMed - in process]
11.

[Advances in head and neck cancers on behalf of the French Intergroup ORL and GORTEC].

Thariat J, Jegoux F, Pointreau Y, Fayette J, Boisselier P, Blanchard P, Alfonsi M, Aupérin A, Bardet E, Bensadoun RJ, Garaud P, Geoffrois L, Graff P, Guigay J, Janot F, Lapeyre M, Lefebvre JL, Martin L, Racadot S, Rolland F, Sire C, Tao Y, Tuchais C, Chibaudel B, Girard-Calais MH, Cornely A, Vintonenko N, Calais G, De Raucourt D, Lacau Saint-Guily J, Bourhis J.

Bull Cancer. 2013 Oct;100(10):983-97. doi: 10.1684/bdc.2013.1829. Review. French.

PMID:
24126183
[PubMed - indexed for MEDLINE]
12.

A double-blind, randomized phase II study to evaluate the safety and efficacy of acetyl-L-carnitine in the prevention of sagopilone-induced peripheral neuropathy.

Campone M, Berton-Rigaud D, Joly-Lobbedez F, Baurain JF, Rolland F, Stenzl A, Fabbro M, van Dijk M, Pinkert J, Schmelter T, de Bont N, Pautier P.

Oncologist. 2013;18(11):1190-1. doi: 10.1634/theoncologist.2013-0061. Epub 2013 Oct 8.

PMID:
24105751
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

A risk-adapted study of cisplatin and etoposide, with or without ifosfamide, in patients with metastatic seminoma: results of the GETUG S99 multicenter prospective study.

Fizazi K, Delva R, Caty A, Chevreau C, Kerbrat P, Rolland F, Priou F, Geoffrois L, Rixe O, Beuzeboc P, Malhaire JP, Culine S, Aubelle MS, Laplanche A.

Eur Urol. 2014 Feb;65(2):381-6. doi: 10.1016/j.eururo.2013.09.004. Epub 2013 Sep 13.

PMID:
24094847
[PubMed - indexed for MEDLINE]
14.

Associated pyoderma gangrenosum, erythema elevatum diutinum, and Sweet's syndrome: the concept of neutrophilic disease.

Caucanas M, Heylen A, Rolland F, Müller G, Olemans C, Sass U, Vanhooteghem O.

Int J Dermatol. 2013 Oct;52(10):1185-8. doi: 10.1111/j.1365-4632.2011.05415.x. Review.

PMID:
24073904
[PubMed - indexed for MEDLINE]
15.

Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy.

Harland S, Staffurth J, Molina A, Hao Y, Gagnon DD, Sternberg CN, Cella D, Fizazi K, Logothetis CJ, Kheoh T, Haqq CM, de Bono JS, Scher HI; COU-AA-301 Investigators.

Eur J Cancer. 2013 Nov;49(17):3648-57. doi: 10.1016/j.ejca.2013.07.144. Epub 2013 Aug 22.

PMID:
23973186
[PubMed - indexed for MEDLINE]
16.

The hybrid four-CBS-domain KINβγ subunit functions as the canonical γ subunit of the plant energy sensor SnRK1.

Ramon M, Ruelens P, Li Y, Sheen J, Geuten K, Rolland F.

Plant J. 2013 Jul;75(1):11-25. doi: 10.1111/tpj.12192. Epub 2013 May 15.

PMID:
23551663
[PubMed - indexed for MEDLINE]
17.

Phase I trial of oral etoposide in combination with radiotherapy in head and neck squamous cell carcinoma - GORTEC 2004-02.

Tao Y, Bardet E, Rosine D, Rolland F, Bompas E, Daly-Schveitzer N, Lusinchi A, Bourhis J.

Radiat Oncol. 2013 Feb 27;8:40. doi: 10.1186/1748-717X-8-40.

PMID:
23445779
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Systemic treatment and medical management of metastatic squamous cell carcinoma of the head and neck: review of the literature and proposal for management changes.

Peyrade F, Cupissol D, Geoffrois L, Rolland F, Borel C, Ciais C, Faivre S, Guigay J.

Oral Oncol. 2013 Jun;49(6):482-91. doi: 10.1016/j.oraloncology.2013.01.005. Epub 2013 Feb 13. Review.

PMID:
23415727
[PubMed - indexed for MEDLINE]
19.

Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPLIN randomized phase II study.

Lefebvre JL, Pointreau Y, Rolland F, Alfonsi M, Baudoux A, Sire C, de Raucourt D, Malard O, Degardin M, Tuchais C, Blot E, Rives M, Reyt E, Tourani JM, Geoffrois L, Peyrade F, Guichard F, Chevalier D, Babin E, Lang P, Janot F, Calais G, Garaud P, Bardet E.

J Clin Oncol. 2013 Mar 1;31(7):853-9. doi: 10.1200/JCO.2012.42.3988. Epub 2013 Jan 22. Erratum in: J Clin Oncol. 2013 May 1;31(13):1702.

PMID:
23341517
[PubMed - indexed for MEDLINE]
Free Article
20.

Are tyrosine kinase inhibitors still active in patients with metastatic renal cell carcinoma previously treated with a tyrosine kinase inhibitor and everolimus? Experience of 36 patients treated in France in the RECORD-1 Trial.

Blesius A, Beuselinck B, Chevreau C, Ravaud A, Rolland F, Oudard S, Escudier B.

Clin Genitourin Cancer. 2013 Jun;11(2):128-33. doi: 10.1016/j.clgc.2012.12.001. Epub 2013 Jan 17.

PMID:
23332872
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk